Form 4: BIOVIE CFO Granted 110,100 Stock Options

BIOVIE Inc.'s Chief Financial Officer, Joanne Wendy Kim, acquired 110,100 stock options with an exercise price of $1.31, vesting over several years.

Summary

• Joanne Wendy Kim, Chief Financial Officer of BIOVIE INC. (BIVI), was granted 110,100 stock options.
• The options have an exercise price of $1.31 per share.
• The earliest transaction date for this grant was January 5, 2026.
• 55% of the options vested on January 5, 2026.
• The remaining options will vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.
• The options have an expiration date of January 5, 2036.
• Following this transaction, Joanne Wendy Kim beneficially owns 110,100 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options is a positive event for aligning management and shareholder interests, but it is a routine compensation matter and not indicative of extraordinary company performance or issues.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.

Future Outlook

The vesting schedule for the stock options indicates a long-term incentive structure for the Chief Financial Officer, with the remaining options vesting annually through January 2029, aligning future performance with equity ownership.

Industry Context

The grant of stock options to key executives like the Chief Financial Officer is a standard practice in the biotechnology and broader corporate sectors. It serves as a common form of executive compensation designed to attract, retain, and motivate leadership by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• Granting stock options to executives is a common practice across industries, including biotechnology, to incentivize long-term performance and align management interests with shareholder value.
• The specified vesting schedule, with an initial immediate vesting followed by annual installments, is typical for retention and performance incentives in executive compensation packages.

Stakeholder Impact

• Shareholders: Potential for increased alignment of management's interests with shareholder value through equity incentives, which could lead to better long-term company performance.

Next Steps

• Vesting of the remaining stock options in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

Key Dates

Keywords

BIOVIE INC., BIVI, Stock Options, CFO, Insider Transaction, Executive Compensation, Form 4